{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:45:10Z","timestamp":1787589910156,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Obstructive hypertrophic cardiomyopathy (oHCM) is associated with both haemodynamic impairment and increased arrhythmic risk, including sudden cardiac death (SCD). Risk stratification relies on the European Society of Cardiology (ESC) HCM Risk-SCD model, complemented by cardiac magnetic resonance (CMR) assessment of myocardial fibrosis. Myosin inhibitors such as mavacamten improve obstruction and induce reverse remodelling, but their impact on arrhythmic risk score remains unknown. The objective was to analyse the impact of mavacamten on the evolution of the ESC rhythm score in patients with obstructive HCM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Consecutive patients with symptomatic oHCM treated with mavacamten between October 2023 and June 2025 at four French referral centres for cardiomyopathies were retrospectively included. Clinical, echocardiographic, and CMR data were collected at baseline and after 6 months of therapy. Arrhythmic risk was calculated using the ESC HCM Risk-SCD model; patients with late gadolinium enhancement (LGE) \u2265 15% of left ventricular (LV) mass were reclassified into the high-risk category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 186 eligible patients, 161 were included (mean age 62 \u00b1 14 years, 55% male). At baseline, arrhythmic risk was classified as high in 6%, intermediate in 9%, and low in 85%. After 6 months of mavacamten, significant improvements were observed in New York Heart Association class (III: 35 to 2%, P &amp;lt; .001), resting LV outflow tract (LVOT) gradient (45 \u00b1 31 to 12 \u00b1 9\u2005mmHg, P &amp;lt; .001), provoked gradient (80 \u00b1 32 to 25 \u00b1 19\u2005mmHg, P &amp;lt; .001) and N-terminal pro\u2013B-type natriuretic peptide (NT-proBNP) levels. The median expected 5-year SCD risk decreased from 2.1% (1.7\u20133) to 1.4% (1.1\u20131.8) (P &amp;lt; .001). In high-risk patients, the score decreased from 7.7% (7.4\u20138.4) to 4.6% (4.5\u20136.0) (P = .001). European Society of Cardiology Risk-SCD reduction was entirely attributable to modifiable parameters: rest\/Valsalva LVOT gradients (\u221233\/\u221257\u2005mmHg), left atrial diameter (\u22121.2\u2005mm), and septal thickness (\u22121.5\u2005mm, all P &amp;lt; .001). Mean HCM Risk Score reduction was 0.7% with heterogeneous inter-patient response, but homogeneous efficacy across centres (P = .206). Considering LGE, the proportion of patients with a high rhythmic risk fell from 16% to 15%. During a median follow-up of 19 months, no patient experienced SCD or required secondary prevention implantable cardioverter-defibrillator; two new non-sustained ventricular tachycardia episodes were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Mavacamten therapy was associated with marked haemodynamic and symptomatic improvements and a reduction in the ESC-based SCD risk in obstructive HCM. While these findings need to be confirmed and were not paralleled by a reduction in arrhythmic events, they suggest that myosin inhibition may influence arrhythmic risk stratification. Prospective studies with longer follow-up are required to determine whether such favourable remodelling translates into true arrhythmic protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag003","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:42:24Z","timestamp":1767876144000},"source":"Crossref","is-referenced-by-count":2,"title":["Effect of mavacamten on sudden cardiac death risk scores in obstructive hypertrophic cardiomyopathy"],"prefix":"10.1093","volume":"13","author":[{"given":"Paolo","family":"Usai","sequence":"first","affiliation":[{"name":"Department of Cardiology, University of Toulouse, Toulouse University Hospital , 1, avenue Jean Poulh\u00e8s, TSA 50032, Toulouse Cedex 9 31059 ,","place":["France"]},{"name":"Cardiac Imaging Center, Toulouse University Hospital, 1, avenue Jean Poulh\u00e8s, 31059, Toulouse Cedex 9 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Cariou","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Toulouse, Toulouse University Hospital , 1, avenue Jean Poulh\u00e8s, TSA 50032, Toulouse Cedex 9 31059 ,","place":["France"]},{"name":"Cardiac Imaging Center, Toulouse University Hospital, 1, avenue Jean Poulh\u00e8s, 31059, Toulouse Cedex 9 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2677-3389","authenticated-orcid":false,"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Rennes, Rennes University Hospital , 2, Rue Henri le Guilloux, 35000, Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-6275","authenticated-orcid":false,"given":"Damien","family":"Eyharts","sequence":"additional","affiliation":[{"name":"Centre de Cardiologie du Pays Basque , 13, avenue de l'Interne Jacques Loeb, 64100, Bayonne ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Assistance Publique\u2014H\u00f4pitaux de Marseille , 264, Rue Saint-Pierre, 13385 ,Marseille Cedex 5 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lucas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Assistance Publique\u2014H\u00f4pitaux de Marseille , 264, Rue Saint-Pierre, 13385 ,Marseille Cedex 5 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Al Wazzan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Rennes, Rennes University Hospital , 2, Rue Henri le Guilloux, 35000, Rennes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloud","family":"Cherbi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Toulouse, Toulouse University Hospital , 1, avenue Jean Poulh\u00e8s, TSA 50032, Toulouse Cedex 9 31059 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Itier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Toulouse, Toulouse University Hospital , 1, avenue Jean Poulh\u00e8s, TSA 50032, Toulouse Cedex 9 31059 ,","place":["France"]},{"name":"Cardiac Imaging Center, Toulouse University Hospital, 1, avenue Jean Poulh\u00e8s, 31059, Toulouse Cedex 9 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Fournier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Toulouse, Toulouse University Hospital , 1, avenue Jean Poulh\u00e8s, TSA 50032, Toulouse Cedex 9 31059 ,","place":["France"]},{"name":"Cardiac Imaging Center, Toulouse University Hospital, 1, avenue Jean Poulh\u00e8s, 31059, Toulouse Cedex 9 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Assistance Publique\u2014H\u00f4pitaux de Marseille , 264, Rue Saint-Pierre, 13385 ,Marseille Cedex 5 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8141-6582","authenticated-orcid":false,"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Toulouse, Toulouse University Hospital , 1, avenue Jean Poulh\u00e8s, TSA 50032, Toulouse Cedex 9 31059 ,","place":["France"]},{"name":"Cardiac Imaging Center, Toulouse University Hospital, 1, avenue Jean Poulh\u00e8s, 31059, Toulouse Cedex 9 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026021112474041600_xvag003-B1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","article-title":"Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review","volume":"79","author":"Maron","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021112474041600_xvag003-B2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.hlc.2018.07.019","article-title":"Sudden cardiac death and ventricular arrhythmias in hypertrophic cardiomyopathy","volume":"28","author":"Moore","year":"2019","journal-title":"Heart Lung Circ"},{"key":"2026021112474041600_xvag003-B3","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/eurheartj\/eht439","article-title":"A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD)","volume":"35","author":"O\u2019Mahony","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021112474041600_xvag003-B4","doi-asserted-by":"publisher","first-page":"f198","DOI":"10.1093\/europace\/eux251","article-title":"Validation of the HCM Risk-SCD model in patients with hypertrophic cardiomyopathy following alcohol septal ablation","volume":"20","author":"Liebregts","year":"2018","journal-title":"Europace"},{"key":"2026021112474041600_xvag003-B5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/CIRCEP.114.002553","article-title":"Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Vriesendorp","year":"2015","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026021112474041600_xvag003-B6","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jcmg.2011.11.021","article-title":"Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy","volume":"5","author":"Green","year":"2012","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026021112474041600_xvag003-B7","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021112474041600_xvag003-B8","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021112474041600_xvag003-B9","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026021112474041600_xvag003-B10","author":"Masri"},{"key":"2026021112474041600_xvag003-B11","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026021112474041600_xvag003-B12","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026021112474041600_xvag003-B13","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021112474041600_xvag003-B14","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.jacep.2022.07.012","article-title":"Temporal and global trends of the incidence of sudden cardiac death in hypertrophic cardiomyopathy","volume":"8","author":"Abdelfattah","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"2026021112474041600_xvag003-B15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1161\/CIRCRESAHA.119.315159","article-title":"Paradigm of sudden death prevention in hypertrophic cardiomyopathy","volume":"125","author":"Maron","year":"2019","journal-title":"Circ Res"},{"key":"2026021112474041600_xvag003-B16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/jce.13194","article-title":"Ventricular tachyarrhythmias in patients with hypertrophic cardiomyopathy and defibrillators: triggers, treatment, and implications","volume":"28","author":"Link","year":"2017","journal-title":"J Cardiovasc Electrophysiol"},{"key":"2026021112474041600_xvag003-B17","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/j.jacasi.2025.05.015","article-title":"Effects of mavacamten on cardiac magnetic resonance features in Chinese patients with obstructive hypertrophic cardiomyopathy","volume":"5","author":"Tian","year":"2025","journal-title":"JACC Asia"},{"key":"2026021112474041600_xvag003-B18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1136\/hrt.2006.099416","article-title":"Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy","volume":"93","author":"Melacini","year":"2007","journal-title":"Heart"},{"key":"2026021112474041600_xvag003-B19","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/bmj.1.5492.895","article-title":"Beta-adrenergic blockade in hypertrophic obstructive cardiomyopathy","volume":"1","author":"Cherian","year":"1966","journal-title":"Br Med J"},{"key":"2026021112474041600_xvag003-B20","doi-asserted-by":"publisher","first-page":"e000963","DOI":"10.1136\/openhrt-2018-000963","article-title":"Factors influencing long-term heart failure mortality in patients with obstructive hypertrophic cardiomyopathy in Western Sweden: probable dose-related protection from beta-blocker therapy","volume":"6","author":"Javidgonbadi","year":"2019","journal-title":"Open Heart"},{"key":"2026021112474041600_xvag003-B21","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"},{"key":"2026021112474041600_xvag003-B22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jacc.2005.02.090","article-title":"Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy","volume":"46","author":"Ommen","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026021112474041600_xvag003-B23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.124.069378","article-title":"Long-term outcomes after septal reduction therapies in obstructive hypertrophic cardiomyopathy: insights from the SHARE registry","volume":"150","author":"Maurizi","year":"2024","journal-title":"Circulation"},{"key":"2026021112474041600_xvag003-B24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.jchf.2014.07.008","article-title":"Revisiting arrhythmic risk after alcohol septal ablation: is the pendulum finally swinging\u2026back to myectomy?","volume":"2","author":"Maron","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026021112474041600_xvag003-B25","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.amjcard.2022.08.028","article-title":"Prediction of sudden cardiac arrest after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: ASA-SCARRE risk score","volume":"184","author":"Veselka","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026021112474041600_xvag003-B26","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jchf.2023.04.018","article-title":"Cardiac myosin inhibitors for managing obstructive hypertrophic cardiomyopathy: JACC: heart failure state-of-the-art review","volume":"11","author":"Ostrominski","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026021112474041600_xvag003-B27","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s44348-025-00052-7","article-title":"Cardiac myosin inhibitors in hypertrophic cardiomyopathy","volume":"33","author":"Lim","year":"2025","journal-title":"J Cardiovasc imaging"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag003\/66464058\/xvag003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvag003\/66464058\/xvag003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/1\/xvag003\/66464058\/xvag003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:47:50Z","timestamp":1770832070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag003\/8430213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag003","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,20]]},"article-number":"xvag003"}}